Novel Use Of Hydroxyurea in an African Region With Malaria
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute
painful episodes and reducing the need for blood transfusions in children with sickle cell
anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan
Africa, the areas with the most children with SCA.
The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for
children with SCA in a malaria endemic region within sub-Saharan Africa.
Phase:
Phase 3
Details
Lead Sponsor:
Indiana University
Collaborators:
Children's Hospital Medical Center, Cincinnati Doris Duke Charitable Foundation Makerere University Mulago Hospital, Uganda